First Oral for MS: New idea, new leader

Congratulations Novartis AG (NVS), but more importantly:

Congratulations MS community.

As expected and anticipated, the FDA has granted priority review for Novartis's Gilenia (Fingolimod or FTY720) -- see:

http://neurologique.blogspot.com/2010/01/filing-and-timing.html

That leaves EMD Serono / Merck KGaA's Cladribine (Movectro/Mylinax) behind in refuse-to0file limbo. Of course, Gilenia leads Laquinimod (Teva), Teriflunomide (Sanofi-Aventis), and BG0012 (Biogen Idec).

So, let's countdown and wait for approval!

- Dr. Daniel Kantor, MD BSE
Medical Director
Neurologique

info@neurologique.org
www.neurologique.org